exai bio

At long last! Great to have this in print; congratulations @jeffzywang and Timmy! And thanks to the ISPY2 team for their support. As is usually the case, these results are a few years old, and our team at @exaibio has been building on these findings: exai.bio/publications

Inspirational story from our friends and collaborators about the need to push the system harder to find cures for rare cancers.  At Exai, we are developing AI models to make high quality, data driven diagnostic solutions accessible for all. centuryofbio.com/p/sid?utm_medi…

That’s a wrap on #SABCS25! Thank you to Dr. Lee Schwartzberg for presenting data demonstrating our platform’s ability to detect early stage breast cancer with high accuracy. #AI #RNA #earlydetection Learn more here: exai.bio/publications/e…

Yesterday our co-founder and CSO Babak Alipanahi presented at the Biotech-Pharma Statistics Workshop (BBSW) about the powerful combination of AI and cell-free RNA to detect early-stage lung cancer in the blood. Thank you to BBSW for this opportunity to share how AI outperforms traditional machine learning methods and will play a pivotal role in the future of liquid biopsy. To learn more, check out our Nature Communications publication: nature.com/articles/s4146…

“Everyone has their own lens on how they perceive their analyte of choice. The winner will be a multi-parametric approach,” said Mass General’s Cesar Martin Castro. “It’s foolhardy to say ctDNA is going to give us all we need. There’s no winner-take-all. It’s just finding the right combinations.” We couldn’t agree more. The future of liquid biopsy will go beyond ctDNA and incorporate novel biomarkers to truly deliver on the promise of early cancer detection. Exai’s RNA-based platform is poised to play a central role in this future and provide the complementary, early stage performance that DNA-based approaches need. statnews.com/2025/07/29/ear…

📣 Leadership News 📣 We’re excited to welcome Michael Nall as CEO and Board Director of Exai Bio. Mike brings decades of diagnostics and commercial expertise that will be instrumental as we scale our RNA- and AI-based liquid biopsy platform and early detection efforts. We’re also proud to announce the addition of three distinguished leaders to our Board of Directors - Steve Kafka, PhD, General Partner at S32, Dusan Perovic, Partner at Two Sigma Ventures and Emir Sandhu, MD, Managing Director at Blue Venture Fund. Their collective insight and leadership will be invaluable as we advance commercial partnerships and expand our impact across cancer care. #CEOAnnouncement #BoardAnnouncement #LiquidBiopsy #RNA #AI #EarlyDetection #BiotechLeadership

Reflecting on a productive week of meetings at @ASCO! Thank you to all those who visited our Innovation Hub booth to learn more about our technology. The theme this year, “Driving Knowledge to Action: Building a Better Future” resonates with all of us at Exai Bio as we do our part to build next generation liquid biopsy tests. #ASCO25 #LiquidBiopsy #AI #RNA

Congratulations to our Board Director Karen Knudsen (@DrKarenKnudsen) MBA PhD for receiving the 2025 Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (@ASCO). We are so grateful for your leadership, passion and the profound impact you have on the cancer community. #ASCO25 #Leadership

💥New Publication Alert in Clinical Cancer Research💥 We are thrilled to announce our latest publication on our novel RNA and generative AI liquid biopsy platform for early colorectal cancer detection. In the independent validation set, we achieved an overall sensitivity of 89% at 90% specificity, with an 80% sensitivity for stage I — an important milestone, as early-stage CRC detection remains a challenge for other blood-based technologies. This study highlights the power of RNA + generative AI to play a central role in delivering on the promise of early cancer detection. #EarlyDetection #LiquidBiopsy #RNA #AI #ColorectalCancer Read the full publication here: aacrjournals.org/clincancerres/…

Exai Bio presented new data demonstrating the power of its RNA and AI based liquid biopsy platform to detect early stage colorectal cancer. Stage I sensitivity in an independent cohort was 80%, exceeding other blood based approaches. Thanks to Amir Momen-Roknabadi (@aroknabadi) for representing Exai Bio at #AACR25! exai.bio/publications/d…

My Density Matters is hosting the 5th Annual Find out My Breast Density Day. DYK almost half of all women have dense breast tissue which means they are at higher risk of developing breast cancer, and mammograms may not be as effective for them? We’re joining My Density Matters to spread awareness that today is Find Out My Breast Density Day – check your mammogram report to empower yourself with this information, talk to your doctor if you have questions, and remind all the women in your life to do the same. At Exai, we are motivated every day to advance our blood test to detect breast cancer early. #BreastDensity #EarlyDetection #Checkyourchart  #Accelerateaction

Together we unite to fight cancer and inspire hope. #WorldCancerDay #UnitedByUnique #EarlyDetection #BreastCancer

Congratulations to our Board Director Karen Knudsen for receiving the 2025 Allen Lichter Visionary Leader Award from the American Society of Clinical Oncology (ASCO). Your tremendous leadership and dedication continue to make a profound impact on cancer care. We are grateful for all you do to improve the lives of cancer patients. #ASCO25 #Exai #Oncology #LeadershipMatters connection.asco.org/do/asco-congra…

#ICYMI, our own Mehran Karimzadeh wrote a blog post about our recent Nature Communications publication demonstrating superior cancer detection performance by Exai’s AI platform compared to traditional machine learning methods. #AI #RNA #EarlyDetection #LungCancer nature.com/articles/s4146… communities.springernature.com/posts/behind-t…

Today, we honor the legacy of Dr. Martin Luther King Jr., whose words continue to inspire us: “The time is always right to do what is right.” At Exai Bio, we are committed to doing what is right—advancing cancer detection and ensuring a future where everyone has access to earlier detection and better health. #MLKDay #Inspiration #Leadership

We are honored to welcome Karen E. Knudsen, MBA, PhD, to our board of directors. As an internationally recognized oncology leader and immediate past CEO of the American Cancer Society and its advocacy affiliate ACS CAN, Karen is deeply committed to ending cancer as we know it. Her guidance will be invaluable as we advance our test to detect breast cancer for women with dense breast tissue. #breastcancer #earlydetection #densebreast #RNA #AI

💥New Publication Alert in Nature Communications 💥 Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods. Generative AI combined with unique RNA biomarkers will play a central role in liquid biopsy and delivering on the promise of early cancer detection.#AI #HealthTech #EarlyDetection #LungCancer Read the full publication here: nature.com/articles/s4146…

Exai was proud to be part of the inaugural RISE UP For Breast Cancer Meeting hosted by UCSF. #breastcancer #womenshealth #UCSF

3 years of innovation never looked so sweet! Celebrating Exai’s 3rd anniversary today, one donut (and breakthrough) at a time! #lifeatexai

Exai was proud to attend #ESMO2024, where we announced new data demonstrating the ability of our RNA liquid biopsy platform to determine breast cancer tumor ER and HER2 status. #liquidbiopsy #breastcancer